A retrospective study found that patients with mismatch repair (MMR)-deficient advanced or recurrent endometrial cancer had numerically longer overall survival (OS) than those with MMR-proficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback